MA53145A - Agents de liaison cd123 et leurs utilisations - Google Patents

Agents de liaison cd123 et leurs utilisations

Info

Publication number: MA53145A
Authority: MA; Morocco
Prior art keywords: liaison; agents; liaison agents
Prior art date: 2014-09-05

Application number

MA053145A

Other languages

English (en)

Inventor

Ricardo Attar

Francois Gaudet

Benjamin C Harman

Yingzhe Li

Jinquan Luo

Ronan Mcdaid

Jennifer F Nemeth

Steven C Pomerantz

Susan H Tam

Alexey Teplyakov

John Wheeler

Sheng-Jiun Wu

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-05

Filing date

2015-09-03

Publication date

2021-05-19

2015-09-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2021-05-19 Publication of MA53145A publication Critical patent/MA53145A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

MA053145A 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations MA53145A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462046682P	2014-09-05	2014-09-05

Publications (1)

Publication Number	Publication Date
MA53145A true MA53145A (fr)	2021-05-19

Family

ID=54150667

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA053145A MA53145A (fr)	2014-09-05	2015-09-03	Agents de liaison cd123 et leurs utilisations
MA40609A MA40609B1 (fr)	2014-09-05	2015-09-03	Agents de liaison cd123 et leurs utilisations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA40609A MA40609B1 (fr)	2014-09-05	2015-09-03	Agents de liaison cd123 et leurs utilisations

Country Status (39)

Country	Link
US (1)	US9850310B2 (fr)
EP (2)	EP3189081B1 (fr)
JP (2)	JP6805130B2 (fr)
KR (1)	KR102540192B1 (fr)
CN (1)	CN107074956B (fr)
AR (1)	AR101765A1 (fr)
AU (1)	AU2015311931B2 (fr)
CA (1)	CA2959171C (fr)
CL (1)	CL2017000515A1 (fr)
CO (1)	CO2017002196A2 (fr)
CR (1)	CR20170079A (fr)
CY (1)	CY1122858T1 (fr)
DK (1)	DK3189081T3 (fr)
EA (1)	EA037647B1 (fr)
EC (1)	ECSP17020812A (fr)
ES (1)	ES2791249T3 (fr)
HR (1)	HRP20200745T1 (fr)
HU (1)	HUE048791T2 (fr)
IL (1)	IL250770B (fr)
JO (1)	JO3568B1 (fr)
LT (1)	LT3189081T (fr)
MA (2)	MA53145A (fr)
ME (1)	ME03724B (fr)
MX (1)	MX384424B (fr)
MY (1)	MY186337A (fr)
NI (1)	NI201700025A (fr)
PE (1)	PE20171556A1 (fr)
PH (1)	PH12017500472A1 (fr)
PL (1)	PL3189081T3 (fr)
PT (1)	PT3189081T (fr)
RS (1)	RS60305B1 (fr)
SG (1)	SG11201701599UA (fr)
SI (1)	SI3189081T1 (fr)
SM (1)	SMT202000253T1 (fr)
TW (1)	TWI693233B (fr)
UA (1)	UA120060C2 (fr)
UY (1)	UY36289A (fr)
WO (1)	WO2016036937A1 (fr)
ZA (1)	ZA201702369B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9150663B2 (en) *	2010-04-20	2015-10-06	Genmab A/S	Heterodimeric antibody Fc-containing proteins and methods for production thereof
TN2018000324A1 (en)	2015-01-23	2020-01-16	Sanofi Sa	ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
US10100118B2 (en)	2015-04-08	2018-10-16	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind CD123
KR20190080992A (ko)	2015-05-21	2019-07-08	하푼 테라퓨틱스, 인크.	삼중특이성 결합 단백질 및 사용 방법
LT3313884T (lt) *	2015-06-29	2021-03-10	Immunogen, Inc.	Anti-cd123 antikūnai, konjugatai ir jų dariniai
IL319047A (en)	2015-08-28	2025-04-01	Amunix Operating Inc	Chimeric polypeptide composition and methods for its preparation and use
US10954301B2 (en)	2015-12-14	2021-03-23	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
PL3461261T3 (pl)	2016-05-20	2025-11-12	Harpoon Therapeutics, Inc.	Białka wiążące jednołańcuchowy fragment zmienny CD3
EP3493844A4 (fr)	2016-05-20	2021-03-24	Harpoon Therapeutics Inc.	Protéine de liaison à l'albumine sérique à domaine unique
KR102187751B1 (ko)	2016-06-06	2020-12-08	에프. 호프만-라 로슈 아게	눈 잔류가 증가된 안과학용 융합 단백질
RU2018145961A (ru)	2016-06-07	2020-07-14	Макродженикс, Инк.	Комбинированная терапия
TWI790206B (zh) *	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) *	2016-07-20	2022-10-21	比利時商健生藥品公司	抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) *	2016-09-19	2018-03-27	上海吉倍生物技术有限公司	高亲和力的抗cd123抗体及其应用
JP7224289B2 (ja) *	2016-09-21	2023-02-17	アプティーボリサーチアンドデベロップメントエルエルシー	Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法
MX2019006045A (es)	2016-11-23	2019-11-11	Harpoon Therapeutics Inc	Proteinas triespecificas dirigidas a psma y metodos de uso.
KR20210087108A (ko)	2016-11-23	2021-07-09	하푼 테라퓨틱스, 인크.	전립선 특이 막 항원 결합 단백질
AU2017366739B2 (en)	2016-12-02	2023-11-23	Angeles Therapeutics, Inc.	Synthetic immune receptors and methods of use thereof
CA3049689A1 (fr) *	2017-02-06	2018-08-09	Dana-Farber Cancer Institute, Inc.	Compositions et methodes pour augmenter la signalisation de recepteurs mediee par des anticorps
BR112019017628A2 (pt)	2017-02-24	2020-07-07	Macrogenics, Inc.	molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11535668B2 (en)	2017-02-28	2022-12-27	Harpoon Therapeutics, Inc.	Inducible monovalent antigen binding protein
JP7181886B2 (ja) *	2017-03-14	2022-12-01	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
SG10202107880XA (en)	2017-05-12	2021-09-29	Harpoon Therapeutics Inc	Mesothelin binding proteins
CA3063362A1 (fr)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Proteines trispecifiques ciblant la msln et procedes d'utilisation
US11472880B2 (en)	2017-08-14	2022-10-18	Morphosys Ag	Humanized antibodies for CD3
WO2019050521A1 (fr) *	2017-09-07	2019-03-14	Macrogenics, Inc.	Schémas posologiques de diacorps bispécifiques cd123 x cd3 dans le traitement de malignités hématologiques
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
PL3694529T3 (pl)	2017-10-13	2024-12-16	Harpoon Therapeutics, Inc.	Trójswoiste białka i sposoby zastosowania
CA3079788C (fr) *	2017-10-27	2023-09-05	Pfizer Inc.	Anticorps et conjugues anticorps-medicament specifiques a cd123 et leurs utilisations
US11795226B2 (en)	2017-12-12	2023-10-24	Macrogenics, Inc.	Bispecific CD16-binding molecules and their use in the treatment of disease
EP3752196A4 (fr)	2018-02-15	2022-03-23	MacroGenics, Inc.	Domaines variants de liaison à cd3 et leur utilisation en polythérapies pour le traitement d'une maladie
EP3765520A1 (fr) *	2018-03-14	2021-01-20	NovImmune SA	Anticorps anti-cd3 epsilon et leurs procédés d'utilisation
MX2020012217A (es)	2018-05-14	2021-03-02	Harpoon Therapeutics Inc	Porción de unión para activación condicional de moléculas de inmunoglobulina.
JOP20200292A1 (ar)	2018-05-16	2020-11-15	Stichting Vumc	Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
MA52777A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Agents de liaison psma et utilisations correspondantes
JP2021524255A (ja)	2018-05-24	2021-09-13	ヤンセンバイオテツク，インコーポレーテツド	単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
JOP20190116A1 (ar) *	2018-05-24	2019-11-24	Janssen Biotech Inc	الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
CN113286817B (zh)	2018-09-25	2025-01-28	哈普恩治疗公司	Dll3结合蛋白及使用方法
EP3882266A4 (fr) *	2018-10-17	2022-07-27	Good T Cells, Inc.	Molécule de liaison spécifique à la protéine lrig-1, et utilisation associée
TWI874341B (zh)	2018-12-18	2025-03-01	美商健生生物科技公司	產生異二聚體抗體之方法
CN119954959A (zh) *	2019-03-11	2025-05-09	詹森生物科技公司	抗Vβ17/抗CD123双特异性抗体
AR118720A1 (es)	2019-04-19	2021-10-27	Janssen Biotech Inc	Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
JP7686571B2 (ja) *	2019-05-08	2025-06-02	ヤンセンバイオテツク，インコーポレーテツド	Ｔ細胞媒介性免疫を調節するための材料及び方法
EP3972998A1 (fr)	2019-05-21	2022-03-30	Novartis AG	Molécules de liaison à cd19 et utilisations de celles-ci
CN113912695B (zh) *	2019-07-24	2023-05-30	暨南大学	靶向cd133的结合蛋白及应用
GB201912681D0 (en)	2019-09-04	2019-10-16	Eth Zuerich	Bispecific binding agent that binds to cd117/c-kit and cd3
KR20220144841A (ko)	2020-02-21	2022-10-27	하푼 테라퓨틱스, 인크.	Flt3 결합 단백질 및 사용 방법
AU2021224787A1 (en)	2020-02-21	2022-10-06	Macrogenics, Inc.	CD137 binding molecules and uses thereof
PE20240020A1 (es)	2020-03-13	2024-01-04	Janssen Biotech Inc	Materiales y metodos para la union de siglec-3/cd33
CA3183325A1 (fr)	2020-05-19	2021-11-25	The Regents Of The University Of California	Polypeptides et vaccins conjugues d'induction de reponses immunitaires
WO2021234560A1 (fr) *	2020-05-19	2021-11-25	Janssen Biotech, Inc.	Compositions comprenant un agent thérapeutique de redirection des lymphocytes t et un inhibiteur de la voie d'adhésion vla 4
KR20230084508A (ko)	2020-09-11	2023-06-13	얀센 바이오테크 인코포레이티드	베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물
IL302276A (en) *	2020-10-23	2023-06-01	Asher Biotherapeutics Inc	Fusions with cd8 antigen binding molecules for modulating immune cell function
AU2021414400A1 (en)	2020-12-31	2023-08-17	Innate Pharma	Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
HRP20250696T1 (hr)	2021-01-28	2025-08-01	Regeneron Pharmaceuticals, Inc.	Sastavi i postupci za liječenje sindroma oslobađanja citokina
KR20240008345A (ko) *	2021-05-18	2024-01-18	얀센 바이오테크 인코포레이티드	T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물
AU2022275666A1 (en)	2021-05-19	2023-12-07	Asher Biotherapeutics, Inc.	Il-21 polypeptides and targeted constructs
AU2022326544A1 (en) *	2021-08-09	2024-02-29	Merck Patent Gmbh	Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023138666A1 (fr) *	2022-01-19	2023-07-27	Utc Therapeutics (Shanghai) Co., Ltd.	Arn circulaire et son utilisation
AU2023254191A1 (en)	2022-04-11	2024-10-17	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
AU2023274452A1 (en)	2022-05-27	2025-01-16	Innate Pharma	Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024173830A2 (fr)	2023-02-17	2024-08-22	Regeneron Pharmaceuticals, Inc.	Cellules nk induites sensibles à des anticorps bispécifiques cd3/taa

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1997024373A1 (fr)	1995-12-29	1997-07-10	Medvet Science Pty. Limited	Antagonistes d'anticorps monoclonaux diriges contre des facteurs de croissance hematopoietiques
US6670127B2 (en)	1997-09-16	2003-12-30	Egea Biosciences, Inc.	Method for assembly of a polynucleotide encoding a target polypeptide
DE69830065T2 (de)	1997-09-16	2006-01-19	Egea Biosciences, LLC, San Diego	Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
AU2005282700A1 (en)	2004-09-02	2006-03-16	Genentech, Inc.	Heteromultimeric molecules
EP3050963B1 (fr)	2005-03-31	2019-09-18	Chugai Seiyaku Kabushiki Kaisha	Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
DE102005028778A1 (de)	2005-06-22	2006-12-28	SUNJÜT Deutschland GmbH	Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US10155816B2 (en)	2005-11-28	2018-12-18	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
US20090182127A1 (en)	2006-06-22	2009-07-16	Novo Nordisk A/S	Production of Bispecific Antibodies
CN101970730A (zh)	2007-12-19	2011-02-09	森托科尔奥索生物科技公司	通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
PL2426148T3 (pl) *	2009-04-27	2016-01-29	Kyowa Hakko Kirin Co Ltd	Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
EP2424567B1 (fr)	2009-04-27	2018-11-21	OncoMed Pharmaceuticals, Inc.	Procédé de fabrication de molécules hétéromultimères
EP3187877A1 (fr) *	2009-09-25	2017-07-05	XOMA Technology Ltd.	Procédés de criblage
US9150663B2 (en)	2010-04-20	2015-10-06	Genmab A/S	Heterodimeric antibody Fc-containing proteins and methods for production thereof
NZ604510A (en) *	2010-08-17	2013-10-25	Csl Ltd	Dilutable biocidal compositions and methods of use
RU2604490C2 (ru)	2010-11-05	2016-12-10	Займворкс Инк.	ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EP2773671B1 (fr)	2011-11-04	2021-09-15	Zymeworks Inc.	Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
EP4053162A1 (fr)	2012-05-18	2022-09-07	Aptevo Research and Development LLC	Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3

2015
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/fr unknown
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/fr active Active
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-03 MX MX2017002891A patent/MX384424B/es unknown
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active Active
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/fr active Active
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2015-09-03 SM SM20200253T patent/SMT202000253T1/it unknown
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/fr not_active Withdrawn
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en not_active Ceased
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/fr not_active Ceased
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
2020
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased

Also Published As

Publication number	Publication date
US9850310B2 (en)	2017-12-26
HRP20200745T1 (hr)	2020-08-07
JP2017529838A (ja)	2017-10-12
EP3722315A1 (fr)	2020-10-14
ME03724B (fr)	2021-01-20
PL3189081T3 (pl)	2020-10-05
SI3189081T1 (sl)	2020-07-31
NI201700025A (es)	2017-06-22
TWI693233B (zh)	2020-05-11
PE20171556A1 (es)	2017-10-27
MA40609B1 (fr)	2020-05-29
SG11201701599UA (en)	2017-03-30
CA2959171A1 (fr)	2016-03-10
CO2017002196A2 (es)	2017-07-28
JO3568B1 (ar)	2020-07-05
EP3189081B1 (fr)	2020-02-19
KR102540192B1 (ko)	2023-06-02
DK3189081T3 (da)	2020-05-04
UY36289A (es)	2016-04-01
LT3189081T (lt)	2020-05-11
CY1122858T1 (el)	2021-05-05
MX384424B (es)	2025-03-14
AU2015311931B2 (en)	2020-09-03
AR101765A1 (es)	2017-01-11
CN107074956A (zh)	2017-08-18
CR20170079A (es)	2017-04-27
MX2017002891A (es)	2017-10-11
JP2021050216A (ja)	2021-04-01
CN107074956B (zh)	2021-11-26
CA2959171C (fr)	2023-11-14
EA201790530A1 (ru)	2018-03-30
TW201625687A (zh)	2016-07-16
CL2017000515A1 (es)	2018-03-16
US20160068605A1 (en)	2016-03-10
AU2015311931A1 (en)	2017-03-16
EA037647B1 (ru)	2021-04-27
MY186337A (en)	2021-07-13
BR112017004322A2 (pt)	2017-12-05
EP3189081A1 (fr)	2017-07-12
PT3189081T (pt)	2020-05-25
ES2791249T3 (es)	2020-11-03
WO2016036937A1 (fr)	2016-03-10
RS60305B1 (sr)	2020-07-31
KR20170049554A (ko)	2017-05-10
SMT202000253T1 (it)	2020-07-08
JP6805130B2 (ja)	2020-12-23
ZA201702369B (en)	2018-12-19
HUE048791T2 (hu)	2020-09-28
ECSP17020812A (es)	2018-07-31
IL250770A0 (en)	2017-04-30
IL250770B (en)	2020-10-29
PH12017500472A1 (en)	2017-07-31
UA120060C2 (uk)	2019-09-25

Publication	Publication Date	Title
MA53145A (fr)	2021-05-19	Agents de liaison cd123 et leurs utilisations
FIC20230014I1 (fi)	2023-03-31	Foslevodopa ja foskarbidopa
EP3334706A4 (fr)	2019-03-13	Pillararènes et utilisations de ceux-ci
MA42622A (fr)	2018-06-20	Agents de liaison à tigit et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
EP3344275A4 (fr)	2019-05-01	Macrocycles peptidomimétiques et leurs utilisations
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
EP3313530A4 (fr)	2019-02-20	Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3337486A4 (fr)	2019-03-06	Composés deutérés et leurs utilisations
EP3294318A4 (fr)	2019-04-03	Macrocycles peptidomimétiques et leurs utilisations
BR112017019682A2 (pt)	2018-07-17	fluoropolímeros modificados
EP3334572A4 (fr)	2019-04-10	Exosquelette
EP3333833A4 (fr)	2019-02-13	Simulateur de technique
EP3341387A4 (fr)	2019-07-24	Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3538261A4 (fr)	2020-06-10	Catalyseurs en pérovskite et leurs utilisations
EP3347021A4 (fr)	2019-07-24	Cyano-thiénotriazoloazépines et leurs utilisations
EP3302490A4 (fr)	2019-01-23	Inhibiteurs d'autotaxine et leurs utilisations
EP3347020A4 (fr)	2019-08-14	Acétamide thiénotriazoldiazépines et leurs utilisations
MA46901A (fr)	2019-10-02	Agents psychotropes et leurs utilisations
EP3450444A4 (fr)	2019-05-01	Composés de type crocine et utilisations correspondantes
MA41022A (fr)	2017-10-03	Ciblage lysosomial et utilisations correspondantes
EP3377897A4 (fr)	2020-01-08	Biocapteurs de lactate et leurs utilisations
EP3370771A4 (fr)	2019-06-19	Conjugués anti-cd3-folate et leurs utilisations
EP3405044A4 (fr)	2019-02-27	Composition bioconservatrice alimentaire et ses utilisations
MA46945A (fr)	2021-03-17	Exopolysaccharides et leurs utilisations